Back

Low-dose bivalent mRNA vaccine is highly effective against different SARS-CoV-2 variants in a transgenic mouse model

Corleis, B.; Hoffmann, D.; Rauch, S.; Fricke, C.; Roth, N.; Gergen, J.; Kovacikova, K.; Schlottau, K.; Halwe, N. J.; Ulrich, L.; Schön, J.; Wernike, K.; Widera, M.; Ciesek, S.; Mueller, S. O.; Mettenleiter, T. C.; Petsch, B.; Beer, M.; Dorhoi, A.

2022-04-20 immunology
10.1101/2022.04.20.485440 bioRxiv
Show abstract

Combining optimized spike (S) protein-encoding mRNA vaccines to target multiple SARS-CoV-2 variants could improve COVID-19 control. We compared monovalent and bivalent mRNA vaccines encoding B.1.351 (Beta) and/or B.1.617.2 (Delta) SARS-CoV-2 S-protein, primarily in a transgenic mouse model and a Wistar rat model. The low-dose bivalent mRNA vaccine contained half the mRNA of each respective monovalent vaccine, but induced comparable neutralizing antibody titres, enrichment of lung-resident memory CD8+ T cells, specific CD4+ and CD8+ responses, and fully protected transgenic mice from SARS-CoV-2 lethality. The bivalent mRNA vaccine significantly reduced viral replication in both Beta- and Delta-challenged mice. Sera from bivalent mRNA vaccine immunized Wistar rats also contained neutralizing antibodies against the B.1.1.529 (Omicron BA.1) variant. These data suggest that low-dose and fit-for-purpose multivalent mRNA vaccines encoding distinct S-proteins is a feasible approach for increasing the potency of vaccines against emerging and co-circulating SARS-CoV-2 variants.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
Nature Communications
○ 5641 papers in training set
Top 9%
18.6%
Similar papers in this journal
2
npj Vaccines
○ 67 papers in training set
Top 0.1%
11.9%
Similar papers in this journal
3
eBioMedicine
○ 183 papers in training set
Top 0.6%
4.3%
Similar papers in this journal
4
Cell Reports Medicine
○ 153 papers in training set
Top 0.6%
4.1%
Similar papers in this journal
5
Science Translational Medicine
● 127 papers in training set
Top 0.6%
3.5%
Similar papers in this journal
6
Molecular Therapy
○ 81 papers in training set
Top 0.5%
3.3%
7
Med
○ 39 papers in training set
Top 0.1%
3.2%
8
Frontiers in Immunology
○ 638 papers in training set
Top 4%
3.2%
50% of probability mass above
9
iScience
○ 1154 papers in training set
Top 9%
2.7%
10
Nature Medicine
○ 125 papers in training set
Top 1%
2.7%
11
Cell
○ 431 papers in training set
Top 4%
2.4%
12
Cell Reports
○ 1498 papers in training set
Top 15%
2.4%
13
Journal for ImmunoTherapy of Cancer
● 75 papers in training set
Top 1.0%
2.1%
14
The Lancet Infectious Diseases
○ 73 papers in training set
Top 0.5%
2.1%
15
Vaccine
○ 203 papers in training set
Top 1%
2.1%
16
Cell Discovery
○ 57 papers in training set
Top 0.4%
1.9%
17
Science
● 477 papers in training set
Top 6%
1.3%
18
Gut
● 40 papers in training set
Top 0.6%
1.1%
19
Human Vaccines & Immunotherapeutics
○ 25 papers in training set
Top 0.3%
1.1%
20
Science Immunology
● 88 papers in training set
Top 2%
1.1%
21
Immunity
○ 67 papers in training set
Top 1%
1.0%
22
Science Advances
● 1243 papers in training set
Top 27%
1.0%
23
Cell Research
○ 51 papers in training set
Top 1%
0.9%
24
Scientific Reports
○ 3612 papers in training set
Top 72%
0.8%
25
Nature Immunology
○ 79 papers in training set
Top 2%
0.8%
26
Molecular Therapy - Methods & Clinical Development
○ 38 papers in training set
Top 0.7%
0.8%
27
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 41%
0.8%
28
Mucosal Immunology
○ 47 papers in training set
Top 0.9%
0.8%
29
Vaccines
○ 198 papers in training set
Top 4%
0.8%
30
PLOS Pathogens
● 820 papers in training set
Top 10%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.